Skip to content
HowShorted

Altimmune, Inc. short interest in 2025

In 2025, Altimmune, Inc.'s disclosed short interest ran from 34.58% of shares outstanding on 15 Jan 2025 to 24.76% on 31 Dec 2025, a change of -9.82 percentage points. The year's high was 38.45% on 30 Jun 2025 and its low 20.89% on 31 Oct 2025, averaging 28.65% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.78 days on 30 Apr 2025. Full history: Altimmune, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Altimmune, Inc. in 2025

2025 in figures

Start of year
34.58% (15 Jan 2025)
End of year
24.76% (31 Dec 2025)
Change
-9.82 pp
High
38.45% (30 Jun 2025)
Low
20.89% (31 Oct 2025)
Average
28.65%
Highest days to cover
13.78 (30 Apr 2025)
SEC filings marked
8

Every report in 2025

Altimmune, Inc. short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 202534.58%9.09
31 Jan 202532.79%12.74
14 Feb 202531.60%12.14
28 Feb 202528.13%8.3710-K filed, results (8-K)
14 Mar 202529.15%5.96
31 Mar 202528.33%9.41
15 Apr 202529.14%9.02
30 Apr 202529.32%13.78
15 May 202527.95%8.1210-Q filed, results (8-K)
30 May 202527.10%10.97
13 Jun 202530.08%6.01
30 Jun 202538.45%1.94
15 Jul 202534.64%4.33
31 Jul 202531.76%7.87
15 Aug 202528.85%9.1510-Q filed, results (8-K)
29 Aug 202530.33%8.59
15 Sep 202528.42%13.17
30 Sep 202529.68%8.70
15 Oct 202524.36%7.25
31 Oct 202520.89%8.70
14 Nov 202522.33%7.1210-Q filed, results (8-K)
28 Nov 202522.21%7.04
15 Dec 202522.75%6.24
31 Dec 202524.76%4.69

See also: Altimmune, Inc.'s full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.